Viveon Health Acquisition Corp.

Viveon Health Acquisition Corp. is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities. The company was founded on August 7, 2020 and is headquartered in Norcross, GA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Viveon Health Acquisition Corp. is a blank check company. It engages in the business of entering a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more target businesses. The company was founded on August 7, 2020 and is headquartered in Atlanta, GA.

New York, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Viveon Health Acquisition Corp (NYSE American: VHAQ, VHAQR, VHAQU) a special purpose acquisition company (the “Company”) re-affirms its commitment to the previously announced business combination with Clearday (CLRD-OTCQX), a San Antonio, Texas-based Healthcare Services company.

VIVEON HEALTHCARE ACQUISITION CORP. CONFIRMS COMMITMENT TO PROCEED WITH BUSINESS COMBINATION PROCESS

Viveon combination with Clearday continues to move forward New York, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Viveon Health Acquisition Corp (NYSE American: VHAQ, VHAQW, VHAQR, VHAQU) a special purpose acquisition company (the “Company”) today is pleased to reconfirm its commitment to the previously announced business combination with Clearday (CLRD-OTCQX), a San Antonio, Texas-based Healthcare Services company. Clearday's mission is to bring digital companionship to the 170 million Americans turning 50 by 2030.

VIVEON HEALTHCARE ACQUISITION CORP CONFIRMS BUSINESS COMBINATION

Atlanta, GA, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Viveon Health Acquisition Corp. (NYSE: VHAQ, VHAQW, VHAQR, VHAQU the “Company”) announces that, as previously disclosed in the Current Report on Form 8-K filed on December 26, 2023 with the United States Securities and Exchange Commission, the Company received a letter from the NYSE American LLC (“NYSE American” or the “Exchange”) on December 22, 2023, stating that the staff of NYSE Regulation has determined to commence proceedings to delist the Company's Common Stock, Units and Rights (collectively, the “Securities”) pursuant to Sections 119(b) and 119(f) of the NYSE American Company Guide because the Company failed to consummate a business combination within 36 months of the effectiveness of its initial public offering registration statement, or such shorter period that the Company specified in its registration statement.

Viveon Health Acquisition Corp. Receives Commencement of Delisting Notice From the NYSE

ATLANTA, GEORGIA, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Viveon Health Acquisition Corp. (Viveon Health Acquisition Corp. (NYSE American: VHAQ, VHAQW, VHAQR, VHAQU) (“Viveon” or the “Company”) announced today that, as previously disclosed in its annual report on Form 10-K for the fiscal year ended December 31, 2022, which was filed on August 24, 2023 with the U.S. Securities and Exchange Commission, the audited financial statements contained an audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company's ability to continue as a going concern. See further discussion in Note 1 to the Company's financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2022. This announcement is made pursuant to NYSE American LLC Company Guide Sections 401(h) and 610(b), which require public announcement of the receipt of an audit opinion containing a going concern paragraph. This announcement does not represent any change or amendment to the Company's financial statements or to its Annual Report on Form 10-K for the year ended December 31, 2022.

VIVEON HEALTH ACQUISITION CORP. RECEIVED AUDIT OPINION WITH GOING CONCERN EXPLANATION

New York, April 25, 2023 (GLOBE NEWSWIRE) -- Viveon Health Acquisition Corp. (Viveon Health Acquisition Corp. (NYSE American: VHAQ, VHAQW, VHAQR, VHAQU) (the “Company”) announced today, that on April 18, 2023, the Company received a notice letter (the “Notice”) from the NYSE Regulation Department (the “Staff”) of the New York Stock Exchange American (“NYSE”) notifying the Company that, based upon the Company's failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “Annual Report”), it was not in compliance with the NYSE American's continued listing requirements.

VIVEON HEALTH ACQUISITION CORP. RECEIVES NYSE NOTICE REGARDING DELAYED FORM 10-K FILING

Norcross, GA– , Feb. 03, 2023 (GLOBE NEWSWIRE) -- Viveon Health Acquisition Corp. (NYSE American: VHAQ, VHAQW, VHAQR, VHAQU) (the “Company” or “Viveon”), a special purpose acquisition company, announced today that it has unilaterally terminated its previously announced agreement and plan of merger with Suneva Medical, Inc. As a result, Viveon will seek an alternative business combination.

Viveon Health Acquisition Corp. Announces Termination of Merger Agreement with Suneva Medical, Inc.

NEW YORK, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Viveon Health Acquisition Corp. (NYSE American: VHAQ, VHAQW, VHAQR, VHAQU), a special purpose acquisition company (the “Company”), today announced that it held a special meeting of stockholders (the “Adjourned Special Meeting”) on January 20, 2023, to, among other things, approve the proposal by the Company to consummate its previously announced initial business combination with Suneva Medical, Inc.  At the Adjourned Special Meeting stockholders voted to adjourn the meeting until February 3, 2023 at 12:00 p.m. Eastern Time.

VIVEON HEALTH ACQUISITION CORP. Announces Adjournment of Special Meeting in Connection with Vote to Consummate its Initial Business Combination with Suneva Medical, Inc. Until February 3, 2023.

NEW YORK, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Viveon Health Acquisition Corp. (NYSE American: VHAQ, VHAQW, VHAQR, VHAQU), a special purpose acquisition company (the “Company”), today announced that it will allow those holders of shares of the Company's common stock sold as part of the units issued in its initial public offering who elected to redeem their common stock (“Redeeming Stockholders”) in connection with the special meeting of stockholders held today at 10:30 AM EST (the “Special Meeting”), to reverse their redemption requests by sending a DTC DWAC (Deposit/Withdrawal At Custodian) request to the Company's transfer agent, Continental Stock Transfer & Trust Company, by 5:00 PM EST on Friday, December 23, 2022.

VIVEON HEALTH ACQUISITION CORP. Announces that Redemption Reversals in Connection with Vote to Consummate its Initial Business Combination with Suneva Medical, Inc. Are Extended Until December 23, 2022.

SAN DIEGO , Sept. 13, 2022 /PRNewswire/ -- Suneva Medical, Inc. ("Suneva" or the "Company"), an innovative medical technology company using regenerative products to change the standard of care in patient treatments, today launched the 30 mL iteration of their Amplifine Platelet Rich Plasma (PRP) gel tubes, which will provide patients and practices with a larger volume of PRP to address varying areas of concern more efficiently.

Suneva Medical Launches 30 mL PRP Gel Tubes of Amplifine, Allowing for More Variety and Efficiency in PRP Treatments

SAN DIEGO & NORCROSS, Ga.--(BUSINESS WIRE)--Viveon Health Acquisition Corp. (NYSE: VHAQ) (“Viveon Health” or “VHAQ”), a special purpose acquisition company, and Suneva Medical, Inc. (“Suneva” or the “Company”), an innovative medical technology company using regenerative medicine to change the standard of care in aesthetic treatments, announced that VHAQ filed a registration statement on Form S-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission ("SEC") on July 13,

Viveon Health Acquisition Corp. Announces Filing of Registration Statement on Form S-4 in Connection with its Proposed Business Combination with Suneva Medical

Canadian Regulators have approved Dermapose®  All-In-One fat sizing syringe U.S. FDA 510(k) clearance for a larger volume Amplifine PRP Gel Tube SAN DIEGO , May 3, 2022 /PRNewswire/ -- Suneva Medical, Inc. ("Suneva" or the "Company"), an innovative medical technology company using regenerative medicine to change the standard of care in aesthetic treatments, and partner Bimini Health Tech ("Bimini"), today announced that they have received approval from Canada's Medical Devices Directorate to market the Dermapose® all-in-one fat sizing syringe in Canada. In the U.S., Suneva has also received an additional 510(K) clearance from  the U.S. Food and Drug Administration (FDA) for its larger volume 30 mL Amplifine PRP gel tube.

Suneva Medical Inc. Announces Multiple Regulatory Approvals in the U.S. and Canada

NEW YORK--(BUSINESS WIRE)--Viveon Health Acquisition Corp. ("Viveon" or the "Company") (NYSE American: VHAQ) today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2021, which was filed on March 31, 2022 with the U.S. Securities and Exchange Commission, the audited financial statements contained an audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company's ability t

Viveon Health Acquisition Corp. Received Audit Opinion with Going Concern Explanation

NORCROSS, Ga. , March 21, 2022 /PRNewswire/ -- Viveon Health Acquisition Corp. (NYSE American: VHAQ) ("Viveon Health" or "VHAQ"), a special purpose acquisition company, announced the approval of its board of directors (the "Board") to extend the date by which Viveon Health has to complete a business combination for an additional three months, to June 28, 2022, and, after June 28, 2022, on a monthly basis for up to six additional months, to December 28, 2022, without further stockholder approval (the "Extension").

Viveon Health Acquisition Corp. Announces Board and Stockholder Approval to Extend Period to Consummate Business Combination

NORCROSS, Ga. , Feb. 11, 2022 /PRNewswire/ -- Viveon Health Acquisition Corp. (NYSE American: VHAQ) ("Viveon Health" or "VHAQ"), a special purpose acquisition company, today announced that it is clarifying certain terms regarding the Annual Meeting of stockholders to be held on March 18, 2022.

Viveon Health Acquisition Corp. Announces Clarified Contribution Terms in Connection with the Extension Related to Merger Agreement with Suneva Medical

SAN DIEGO, Feb. 8, 2022 /PRNewswire/ -- Suneva Medical, Inc. ("Suneva" or the "Company"), an innovative medical technology company using regenerative medicine to change the standard of care in aesthetic treatments, today announced that it reached a milestone of distributing more than 1 million syringes of  Bellafill® at the close of 2021. Bellafill, which has been available for regenerative aesthetic use since 2007, is Suneva's five-year, FDA-approved filler for the correction of nasolabial folds and moderate to severe, atrophic, distensible facial acne scars on people's cheeks.

Suneva Surpasses 1 Million Syringes of Bellafill® Distributed Since the Biostimulator's Inception

SAN DIEGO, Jan. 28, 2022 /PRNewswire/ -- Suneva Medical, Inc. ("Suneva" or the "Company"), an innovative medical technology company using regenerative medicine to change the standard of care in aesthetic treatments, today announced that the U.S. Food and Drug Administration (FDA) accepted updates to the Plasma IQ ™ label, including the removal of the product's eye contraindication. The removal of this specific contraindication was due in part to a compilation of literature provided to the FDA showing the safety and efficacy of the ablative device on skin tissue, particularly around the eye area.

FDA Accepts Label Update for Plasma IQ™, the First FDA-Cleared Handheld Plasma Energy Device

Suneva Medical Inc, medical aesthetics player, will soon form a reverse merger with Viveon Health Acquisition Corp (NYSE: VHAQ), a special purpose acquisition company. Viveon Health went public through an initial public offering in December 2020 that brought in proceeds of $201 million.

Regenerative Aesthetics Firm Suneva Medical Gets SPAC Support To Go Public

SAN DIEGO and  NORCROSS, Ga., Jan. 12, 2022 /PRNewswire/ -- Suneva Medical, Inc. ("Suneva" or the "Company"), an innovative medical technology company using regenerative medicine to change the standard of care in aesthetic treatments, and Viveon Health Acquisition Corp. (NYSE American: VHAQ) ("Viveon Health" or "VHAQ"), a special purpose acquisition company, announced today that they have entered into a definitive merger agreement.

News for Viveon Health Acquisition Corp. Stock (VHAQ)